Compare EPR Properties (EPR) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? EPR Properties trades at $54.41 (market cap $4.17B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 14.1× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 45 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| EPR | TAK | |
|---|---|---|
Market Cap | $4.17B | $58.74B |
Volume | 992,716 | 3,110,994 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $19.05 |
52-Week Low | $48.71 | $13.23 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $7.68B | $86.65B |
Dividend Yield | 6.84% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $54.08, down 2.15% today, with a bearish technical signal and oversold RSI suggesting potential reversal. The REIT maintains strong fundamentals with 91.41% gross margins and consistent dividend payments, though recent earnings showed a Q1 miss. Analyst consensus remains positive with a $65.50 price target, representing 21% upside from current levels.
EPR offers attractive income potential with a 6.5% dividend yield and diversified real estate portfolio, but faces headwinds from rising interest rates and mixed earnings performance. The stock's current valuation at 17.44 P/E appears reasonable, though technical weakness and negative cash flow projections for 2026 warrant caution for near-term investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
